This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://dx.doi.org/10.1097/
n5http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q69794916
rdf:type
wikibase:Item
schema:description
scientific article published on 01 April 1985 artículu científicu espublizáu n'abril de 1985 наукова стаття, опублікована у квітні 1985 article scientifique publié en 1985 im April 1985 veröffentlichter wissenschaftlicher Artikel wetenschappelijk artikel
p:P577
wds:Q69794916-CB1A076B-EB8E-4B5B-80FB-5329A937DADA
wdt:P577
1985-04-01T00:00:00Z
p:P2093
wds:Q69794916-CC45D84C-A2D7-4308-8838-C210F1D925F3 wds:Q69794916-1FA37834-1898-4111-BCC1-8266199534FF wds:Q69794916-22618030-FBC2-4AE3-A4D9-343C501A5B6A
wdt:P2093
M J Ravry G A Omura R Birch
rdfs:label
Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial Phase II evaluation of maytansine
skos:prefLabel
Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial Phase II evaluation of maytansine
schema:name
Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial Phase II evaluation of maytansine
p:P1476
wds:Q69794916-A63B1925-F5FD-402E-83EA-7FFFAFCBF2AC
wdt:P1476
Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial
p:P304
wds:Q69794916-1A618A2F-B8DB-425C-8D56-1DD67BAA1267
wdt:P304
148-150
p:P31
wds:Q69794916-084C209F-5D59-4CB4-9DC6-551D9C917F62
wdt:P31
wd:Q13442814
p:P921
wds:Q69794916-D12EA4E8-73DA-4CD8-AF0A-B6533478B690 wds:Q69794916-AA7482D2-C349-4858-AE7A-163771A5732B
wdt:P921
wd:Q6720157 wd:Q42824440
p:P698
wds:Q69794916-A9AA4513-F642-4D7D-991D-2396A4ED2368
wdtn:P698
n5:3834790
wdt:P698
3834790
p:P1433
wds:Q69794916-24827B1F-A9F7-491F-935A-C40E4AC4F690
wdt:P1433
wd:Q2886177
p:P433
wds:Q69794916-C5831D56-AF2F-452A-92DC-500C3CA3351B
p:P478
wds:Q69794916-D72D4ECD-FD25-4E83-B18F-5C8B017E5D43
wdt:P433
2
wdt:P478
8
p:P356
wds:Q69794916-FD97730B-3954-42D4-B4E7-9A4B3BEFEAC0
wdtn:P356
n12:00000421-198504000-00007
wdt:P356
10.1097/00000421-198504000-00007